Furthermore, based on SEPN1-related long non-coding RNAs (lncRNAs), we developed and validated an SEPN1-related risk score (SRS) and associated nomogram, and identified potential anti-glioma drugs based on SRS. Here, SELENON is linked to central nervous system cancer.